Danaher to Buy Pall for $13.8B, Split Into Two Publicly Traded Firms | GenomeWeb

NEW YORK (GenomeWeb) – Danaher today announced a definitive merger agreement to purchase Pall in an all-cash deal totaling approximately $13.8 billion. 

Under the terms of the deal, which is expected to be completed around the end of the year, Danaher will pay $127.20 for each share of Pall's stock. The $13.8 billion price tag includes assumed debt and is net of acquired cash. The boards of Danaher and Pall have unanimously approved the merger. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.